Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA-repair defects and Platinum-based chemotherapy in mCRPC
ChiCTR-OPC-16009563Phase 4Recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Oct 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxaliplatin and pemetrexed in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Huadong Hospital, Fudan University. Primary endpoint: Response Rate. Started Oct 2016; status: recruiting.
02
Drugs
oxaliplatinpemetrexed
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR-OPC-16009563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16009563.